conducted targeted metabolomics analysis on tumours excised from patients with early‐stage IMPC (n = 25) and IDC (n = 26), and through integrating mass spectrometry, RNA sequencing, and ChIP‐sequencing data, they found overexpression of PRMT3 in IMPC, with high levels of PRMT3 associated with poor clinical prognosis. This evidence concerns the gene PRMT3 and neoplasm.